Global Piriformis Syndrome Market: Industry Analysis and forecast 2019 – 2027: By Treatment, Cause, End-User,and Region.

Global Piriformis Syndrome Market size was valued US$ XX Mn. in 2019 and the total revenue is expected to grow at 7.8% from2019 to 2027, reaching nearly US$ XX Mn. To know about the Research Methodology :- Request Free Sample Report The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis. Piriformis syndrome is a medical condition of sciatic nerve set up at the level of the ischial tuberosity. The general causes of piriformis syndrome are spasms, overuse injury, and trauma. The piriformis syndrome initial treatments contain physical therapy combined with the use of anti-inflammatory analgesics, drugs, and muscle relaxants to decrease spasm, pain, and inflammation. Developing markets and huge investment in R&D are the factors responsible for the growth of piriformis syndrome market globally. Investment by companies in spreading awareness about the dominance of piriformis syndrome and its treatments is expected to contribute to the growth of the global market for piriformis syndrome. As per the NCBI (National Center for Biotechnology Information), the projected new cases of sciatica and back pain is 40 million per year, and the incidence rate of piriformis syndrome is about 2.4 million yearly. On the other hand, high treatment cause and limited revenue opportunities are some of the factors that are expected to restrict the piriformis syndrome market growth over 2019-2027. Likewise, the report contains a detailed study of factors that will drive and restrain the growth of the piriformis syndrome market globally. The MMR report covers the segments in the piriformis syndrome market such as treatment, cause, and end-user. Based on the cause, trauma segment was valued US$ XX Mn. in 2019 and is expected to reach a value of US$ XX Mn.n by 2027, with a CAGR of XX.78% during the forecast period. Trauma to the buttock leads to spasm and inflammation of the muscle. A past of trauma is typically elicited in nearly 50% of the cases: The trauma is commonly not dramatic and may occur many months before the early symptoms. North America piriformis syndrome market was valued US$ XX Mn. in 2019 and is expected to reach a value of US$ XX Mn. by 2027, with a CAGR of XX.30% during 2019-2027. This is attributed to the large availability of treatment options in the USA and a high prevalence of piriformis syndrome. The U.S. is a leading country in North America for piriformis syndrome market. Such as, along with the Centers for Disease Control & Prevention, the total health spending in the U.S. was reported to be US$ 3.2 trillion in 2015. However, Europe accounts for the second-highest revenue share contribution to the piriformis syndrome market owing to the government support towards R&D expenditure. The piriformis syndrome market growth in EU is led by economies such as France and Germany. The MMR report also focuses on global major leading industry players of piriformis syndrome market providing information like company profiles, and revenue. Novartis Company would acquire Advanced Accelerator Applications in 2017; this is for US$3.9 Bn, paying US$41 per ordinary share & US$82 per American depositary share representing a 47% premium. The objective of the report is to present a comprehensive analysis of the Global Piriformis Syndrome Marketincluding all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Piriformis Syndrome Marketdynamics, structure by analyzing the market segments and projects the Global Piriformis Syndrome Marketsize. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Piriformis Syndrome Market make the report investor’s guide.

Scope of the Global Piriformis Syndrome Market: Inquire before buying

Global Piriformis Syndrome Market, by Treatment

• Medication o NSAIDS  Naproxen  Ibuprofen  Others o Piriformis Muscle Injection  Botox Injection  Steroid Injection  Others • Physical Therapy o Acupuncture o Prolotherapy • Osteopathic Manipulative Treatment (OMT) o Surgery o Others

Global Piriformis Syndrome Market, by Cause

• Trauma • Spasms • Overuse injury • Others

Global Piriformis Syndrome Market, by End-User

• Hospitals & Clinics • Diagnostic Centers • Others

Global Piriformis Syndrome Market, by Region

• Asia Pacific  India  China  Japan  South Korea  Australia  Indonesia  Malaysia  Vietnam  Rest of Asia • North America  U.S.  Canada • Europe  U.K  Germany  France  Russia  Spain  Italy  Sweden • South America  Mexico  Brazil  Rest of South America • Middle East & Africa  GCC  South Africa  Rest of MEA

Key players operating in the Global Piriformis Syndrome Market

• Sanofi S.A. • Bayer AG • Novartis AG • AstraZeneca • Endo Pharmaceuticals • Teva Pharmaceuticals • Omron Healthcare • DePuy Synthes Companies • Miracle Stretch, LLC • Flex Pharma, Inc. • Nidd valley medical • SEIRIN Corporation
Global Piriformis Syndrome Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Piriformis Syndrome Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Piriformis Syndrome Market Analysis and Forecast 6.1. Piriformis Syndrome Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Piriformis Syndrome Market Analysis and Forecast, By Cause 7.1. Introduction and Definition 7.2. Key Findings 7.3. Piriformis Syndrome Market Value Share Analysis, By Cause 7.4. Piriformis Syndrome Market Size (US$ Mn) Forecast, By Cause 7.5. Piriformis Syndrome Market Analysis, By Cause 7.6. Piriformis Syndrome Market Attractiveness Analysis, By Cause 8. Global Piriformis Syndrome Market Analysis and Forecast, By Treatment 8.1. Introduction and Definition 8.2. Key Findings 8.3. Piriformis Syndrome Market Value Share Analysis, By Treatment 8.4. Piriformis Syndrome Market Size (US$ Mn) Forecast, By Treatment 8.5. Piriformis Syndrome Market Analysis, By Treatment 8.6. Piriformis Syndrome Market Attractiveness Analysis, By Treatment 9. Global Piriformis Syndrome Market Analysis and Forecast, By End-User 9.1. Introduction and Definition 9.2. Key Findings 9.3. Piriformis Syndrome Market Value Share Analysis, By End-User 9.4. Piriformis Syndrome Market Size (US$ Mn) Forecast, By End-User 9.5. Piriformis Syndrome Market Analysis, By End-User 9.6. Piriformis Syndrome Market Attractiveness Analysis, By End-User 10. Global Piriformis Syndrome Market Analysis, by Region 10.1. Piriformis Syndrome Market Value Share Analysis, by Region 10.2. Piriformis Syndrome Market Size (US$ Mn) Forecast, by Region 10.3. Piriformis Syndrome Market Attractiveness Analysis, by Region 11. North America Piriformis Syndrome Market Analysis 11.1. Key Findings 11.2. North America Piriformis Syndrome Market Overview 11.3. North America Piriformis Syndrome Market Value Share Analysis, By Cause 11.4. North America Piriformis Syndrome Market Forecast, By Cause 11.4.1. Trauma 11.4.2. Spasms 11.4.3. Overuse injury 11.4.4. Other 11.5. North America Piriformis Syndrome Market Value Share Analysis, By Treatment 11.6. North America Piriformis Syndrome Market Forecast, By Treatment 11.6.1. Medication 11.6.1.1. NSAIDS 11.6.1.1.1. Naproxen 11.6.1.1.2. Ibuprofen 11.6.1.1.3. Others 11.6.1.2. Piriformis Muscle Injection 11.6.1.2.1. Botox Injection 11.6.1.2.2. Steroid Injection 11.6.1.2.3. Others 11.6.2. Physical Therapy 11.6.2.1. Acupuncture 11.6.2.2. Prolotherapy 11.6.3. Osteopathic Manipulative Treatment (OMT) 11.6.3.1. Surgery 11.6.3.2. Others 11.7. North America Piriformis Syndrome Market Value Share Analysis, By End-User 11.8. North America Piriformis Syndrome Market Forecast, By End-User 11.8.1. Hospitals & Clinics 11.8.2. Diagnostic Centers 11.8.3. Other 11.9. North America Piriformis Syndrome Market Value Share Analysis, by Country 11.10. North America Piriformis Syndrome Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Piriformis Syndrome Market Analysis, by Country 11.12. U.S. Piriformis Syndrome Market Forecast, By Cause 11.12.1. Trauma 11.12.2. Spasms 11.12.3. Overuse injury 11.12.4. Other 11.13. U.S. Piriformis Syndrome Market Forecast, By Treatment 11.13.1. Medication 11.13.1.1. NSAIDS 11.13.1.1.1. Naproxen 11.13.1.1.2. Ibuprofen 11.13.1.1.3. Others 11.13.1.2. Piriformis Muscle Injection 11.13.1.2.1. Botox Injection 11.13.1.2.2. Steroid Injection 11.13.1.2.3. Others 11.13.2. Physical Therapy 11.13.2.1. Acupuncture 11.13.2.2. Prolotherapy 11.13.3. Osteopathic Manipulative Treatment (OMT) 11.13.3.1. Surgery 11.13.3.2. Others 11.14. U.S. Piriformis Syndrome Market Forecast, By End-User 11.14.1. Hospitals & Clinics 11.14.2. Diagnostic Centers 11.14.3. Other 11.15. Canada Piriformis Syndrome Market Forecast, By Cause 11.15.1. Trauma 11.15.2. Spasms 11.15.3. Overuse injury 11.15.4. Other 11.16. Canada Piriformis Syndrome Market Forecast, By Treatment 11.16.1. Medication 11.16.1.1. NSAIDS 11.16.1.1.1. Naproxen 11.16.1.1.2. Ibuprofen 11.16.1.1.3. Others 11.16.1.2. Piriformis Muscle Injection 11.16.1.2.1. Botox Injection 11.16.1.2.2. Steroid Injection 11.16.1.2.3. Others 11.16.2. Physical Therapy 11.16.2.1. Acupuncture 11.16.2.2. Prolotherapy 11.16.3. Osteopathic Manipulative Treatment (OMT) 11.16.3.1. Surgery 11.16.3.2. Others 11.17. Canada Piriformis Syndrome Market Forecast, By End-User 11.17.1. Hospitals & Clinics 11.17.2. Diagnostic Centers 11.17.3. Other 11.18. North America Piriformis Syndrome Market Attractiveness Analysis 11.18.1. By Cause 11.18.2. By Treatment 11.18.3. By End-User 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Piriformis Syndrome Market Analysis 12.1. Key Findings 12.2. Europe Piriformis Syndrome Market Overview 12.3. Europe Piriformis Syndrome Market Value Share Analysis, By Cause 12.4. Europe Piriformis Syndrome Market Forecast, By Cause 12.4.1. Trauma 12.4.2. Spasms 12.4.3. Overuse injury 12.4.4. Other 12.5. Europe Piriformis Syndrome Market Value Share Analysis, By Treatment 12.6. Europe Piriformis Syndrome Market Forecast, By Treatment 12.6.1. Medication 12.6.1.1. NSAIDS 12.6.1.1.1. Naproxen 12.6.1.1.2. Ibuprofen 12.6.1.1.3. Others 12.6.1.2. Piriformis Muscle Injection 12.6.1.2.1. Botox Injection 12.6.1.2.2. Steroid Injection 12.6.1.2.3. Others 12.6.2. Physical Therapy 12.6.2.1. Acupuncture 12.6.2.2. Prolotherapy 12.6.3. Osteopathic Manipulative Treatment (OMT) 12.6.3.1. Surgery 12.6.3.2. Others 12.7. Europe Piriformis Syndrome Market Value Share Analysis, By End-User 12.8. Europe Piriformis Syndrome Market Forecast, By End-User 12.8.1. Hospitals & Clinics 12.8.2. Diagnostic Centers 12.8.3. Other 12.9. Europe Piriformis Syndrome Market Value Share Analysis, by Country 12.10. Europe Piriformis Syndrome Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Piriformis Syndrome Market Analysis, by Country 12.12. Germany Piriformis Syndrome Market Forecast, By Cause 12.12.1. Trauma 12.12.2. Spasms 12.12.3. Overuse injury 12.12.4. Other 12.13. Germany Piriformis Syndrome Market Forecast, By Treatment 12.13.1. Medication 12.13.1.1. NSAIDS 12.13.1.1.1. Naproxen 12.13.1.1.2. Ibuprofen 12.13.1.1.3. Others 12.13.1.2. Piriformis Muscle Injection 12.13.1.2.1. Botox Injection 12.13.1.2.2. Steroid Injection 12.13.1.2.3. Others 12.13.2. Physical Therapy 12.13.2.1. Acupuncture 12.13.2.2. Prolotherapy 12.13.3. Osteopathic Manipulative Treatment (OMT) 12.13.3.1. Surgery 12.13.3.2. Others 12.14. Germany Piriformis Syndrome Market Forecast, By End-User 12.14.1. Hospitals & Clinics 12.14.2. Diagnostic Centers 12.14.3. Other 12.15. U.K. Piriformis Syndrome Market Forecast, By Cause 12.15.1. Trauma 12.15.2. Spasms 12.15.3. Overuse injury 12.15.4. Other 12.16. U.K. Piriformis Syndrome Market Forecast, By Treatment 12.16.1. Medication 12.16.1.1. NSAIDS 12.16.1.1.1. Naproxen 12.16.1.1.2. Ibuprofen 12.16.1.1.3. Others 12.16.1.2. Piriformis Muscle Injection 12.16.1.2.1. Botox Injection 12.16.1.2.2. Steroid Injection 12.16.1.2.3. Others 12.16.2. Physical Therapy 12.16.2.1. Acupuncture 12.16.2.2. Prolotherapy 12.16.3. Osteopathic Manipulative Treatment (OMT) 12.16.3.1. Surgery 12.16.3.2. Others 12.17. U.K. Piriformis Syndrome Market Forecast, By End-User 12.17.1. Hospitals & Clinics 12.17.2. Diagnostic Centers 12.17.3. Other 12.18. France Piriformis Syndrome Market Forecast, By Cause 12.18.1. Trauma 12.18.2. Spasms 12.18.3. Overuse injury 12.18.4. Other 12.19. France Piriformis Syndrome Market Forecast, By Treatment 12.19.1. Medication 12.19.1.1. NSAIDS 12.19.1.1.1. Naproxen 12.19.1.1.2. Ibuprofen 12.19.1.1.3. Others 12.19.1.2. Piriformis Muscle Injection 12.19.1.2.1. Botox Injection 12.19.1.2.2. Steroid Injection 12.19.1.2.3. Others 12.19.2. Physical Therapy 12.19.2.1. Acupuncture 12.19.2.2. Prolotherapy 12.19.3. Osteopathic Manipulative Treatment (OMT) 12.19.3.1. Surgery 12.19.3.2. Others 12.20. France Piriformis Syndrome Market Forecast, By End-User 12.20.1. Hospitals & Clinics 12.20.2. Diagnostic Centers 12.20.3. Other 12.21. Italy Piriformis Syndrome Market Forecast, By Cause 12.21.1. Trauma 12.21.2. Spasms 12.21.3. Overuse injury 12.21.4. Other 12.22. Italy Piriformis Syndrome Market Forecast, By Treatment 12.22.1. Medication 12.22.1.1. NSAIDS 12.22.1.1.1. Naproxen 12.22.1.1.2. Ibuprofen 12.22.1.1.3. Others 12.22.1.2. Piriformis Muscle Injection 12.22.1.2.1. Botox Injection 12.22.1.2.2. Steroid Injection 12.22.1.2.3. Others 12.22.2. Physical Therapy 12.22.2.1. Acupuncture 12.22.2.2. Prolotherapy 12.22.3. Osteopathic Manipulative Treatment (OMT) 12.22.3.1. Surgery 12.22.3.2. Others 12.23. Italy Piriformis Syndrome Market Forecast, By End-User 12.23.1. Hospitals & Clinics 12.23.2. Diagnostic Centers 12.23.3. Other 12.24. Spain Piriformis Syndrome Market Forecast, By Cause 12.24.1. Trauma 12.24.2. Spasms 12.24.3. Overuse injury 12.24.4. Other 12.25. Spain Piriformis Syndrome Market Forecast, By Treatment 12.25.1. Medication 12.25.1.1. NSAIDS 12.25.1.1.1. Naproxen 12.25.1.1.2. Ibuprofen 12.25.1.1.3. Others 12.25.1.2. Piriformis Muscle Injection 12.25.1.2.1. Botox Injection 12.25.1.2.2. Steroid Injection 12.25.1.2.3. Others 12.25.2. Physical Therapy 12.25.2.1. Acupuncture 12.25.2.2. Prolotherapy 12.25.3. Osteopathic Manipulative Treatment (OMT) 12.25.3.1. Surgery 12.25.3.2. Others 12.26. Spain Piriformis Syndrome Market Forecast, By End-User 12.26.1. Hospitals & Clinics 12.26.2. Diagnostic Centers 12.26.3. Other 12.27. Rest of Europe Piriformis Syndrome Market Forecast, By Cause 12.27.1. Trauma 12.27.2. Spasms 12.27.3. Overuse injury 12.27.4. Other 12.28. Rest of Europe Piriformis Syndrome Market Forecast, By Treatment 12.28.1. Medication 12.28.1.1. NSAIDS 12.28.1.1.1. Naproxen 12.28.1.1.2. Ibuprofen 12.28.1.1.3. Others 12.28.1.2. Piriformis Muscle Injection 12.28.1.2.1. Botox Injection 12.28.1.2.2. Steroid Injection 12.28.1.2.3. Others 12.28.2. Physical Therapy 12.28.2.1. Acupuncture 12.28.2.2. Prolotherapy 12.28.3. Osteopathic Manipulative Treatment (OMT) 12.28.3.1. Surgery 12.28.3.2. Others 12.29. Rest Of Europe Piriformis Syndrome Market Forecast, By End-User 12.29.1. Hospitals & Clinics 12.29.2. Diagnostic Centers 12.29.3. Other 12.30. Europe Piriformis Syndrome Market Attractiveness Analysis 12.30.1. By Cause 12.30.2. By Treatment 12.30.3. By End-User 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Piriformis Syndrome Market Analysis 13.1. Key Findings 13.2. Asia Pacific Piriformis Syndrome Market Overview 13.3. Asia Pacific Piriformis Syndrome Market Value Share Analysis, By Cause 13.4. Asia Pacific Piriformis Syndrome Market Forecast, By Cause 13.4.1. Trauma 13.4.2. Spasms 13.4.3. Overuse injury 13.4.4. Other 13.5. Asia Pacific Piriformis Syndrome Market Value Share Analysis, By Treatment 13.6. Asia Pacific Piriformis Syndrome Market Forecast, By Treatment 13.6.1. Medication 13.6.1.1. NSAIDS 13.6.1.1.1. Naproxen 13.6.1.1.2. Ibuprofen 13.6.1.1.3. Others 13.6.1.2. Piriformis Muscle Injection 13.6.1.2.1. Botox Injection 13.6.1.2.2. Steroid Injection 13.6.1.2.3. Others 13.6.2. Physical Therapy 13.6.2.1. Acupuncture 13.6.2.2. Prolotherapy 13.6.3. Osteopathic Manipulative Treatment (OMT) 13.6.3.1. Surgery 13.6.3.2. Others 13.7. Asia Pacific Piriformis Syndrome Market Value Share Analysis, By End-User 13.8. Asia Pacific Piriformis Syndrome Market Forecast, By End-User 13.8.1. Hospitals & Clinics 13.8.2. Diagnostic Centers 13.8.3. Other 13.9. Asia Pacific Piriformis Syndrome Market Value Share Analysis, by Country 13.10. Asia Pacific Piriformis Syndrome Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Piriformis Syndrome Market Analysis, by Country 13.12. China Piriformis Syndrome Market Forecast, By Cause 13.12.1. Trauma 13.12.2. Spasms 13.12.3. Overuse injury 13.12.4. Other 13.13. China Piriformis Syndrome Market Forecast, By Treatment 13.13.1. Medication 13.13.1.1. NSAIDS 13.13.1.1.1. Naproxen 13.13.1.1.2. Ibuprofen 13.13.1.1.3. Others 13.13.1.2. Piriformis Muscle Injection 13.13.1.2.1. Botox Injection 13.13.1.2.2. Steroid Injection 13.13.1.2.3. Others 13.13.2. Physical Therapy 13.13.2.1. Acupuncture 13.13.2.2. Prolotherapy 13.13.3. Osteopathic Manipulative Treatment (OMT) 13.13.3.1. Surgery 13.13.3.2. Others 13.14. China Piriformis Syndrome Market Forecast, By End-User 13.14.1. Hospitals & Clinics 13.14.2. Diagnostic Centers 13.14.3. Other 13.15. India Piriformis Syndrome Market Forecast, By Cause 13.15.1. Trauma 13.15.2. Spasms 13.15.3. Overuse injury 13.15.4. Other 13.16. India Piriformis Syndrome Market Forecast, By Treatment 13.16.1. Medication 13.16.1.1. NSAIDS 13.16.1.1.1. Naproxen 13.16.1.1.2. Ibuprofen 13.16.1.1.3. Others 13.16.1.2. Piriformis Muscle Injection 13.16.1.2.1. Botox Injection 13.16.1.2.2. Steroid Injection 13.16.1.2.3. Others 13.16.2. Physical Therapy 13.16.2.1. Acupuncture 13.16.2.2. Prolotherapy 13.16.3. Osteopathic Manipulative Treatment (OMT) 13.16.3.1. Surgery 13.16.3.2. Others 13.17. India Piriformis Syndrome Market Forecast, By End-User 13.17.1. Hospitals & Clinics 13.17.2. Diagnostic Centers 13.17.3. Other 13.18. Japan Piriformis Syndrome Market Forecast, By Cause 13.18.1. Trauma 13.18.2. Spasms 13.18.3. Overuse injury 13.18.4. Other 13.19. Japan Piriformis Syndrome Market Forecast, By Treatment 13.19.1. Medication 13.19.1.1. NSAIDS 13.19.1.1.1. Naproxen 13.19.1.1.2. Ibuprofen 13.19.1.1.3. Others 13.19.1.2. Piriformis Muscle Injection 13.19.1.2.1. Botox Injection 13.19.1.2.2. Steroid Injection 13.19.1.2.3. Others 13.19.2. Physical Therapy 13.19.2.1. Acupuncture 13.19.2.2. Prolotherapy 13.19.3. Osteopathic Manipulative Treatment (OMT) 13.19.3.1. Surgery 13.19.3.2. Others 13.20. Japan Piriformis Syndrome Market Forecast, By End-User 13.20.1. Hospitals & Clinics 13.20.2. Diagnostic Centers 13.20.3. Other 13.21. ASEAN Piriformis Syndrome Market Forecast, By Cause 13.21.1. Trauma 13.21.2. Spasms 13.21.3. Overuse injury 13.21.4. Other 13.22. ASEAN Piriformis Syndrome Market Forecast, By Treatment 13.22.1. Medication 13.22.1.1. NSAIDS 13.22.1.1.1. Naproxen 13.22.1.1.2. Ibuprofen 13.22.1.1.3. Others 13.22.1.2. Piriformis Muscle Injection 13.22.1.2.1. Botox Injection 13.22.1.2.2. Steroid Injection 13.22.1.2.3. Others 13.22.2. Physical Therapy 13.22.2.1. Acupuncture 13.22.2.2. Prolotherapy 13.22.3. Osteopathic Manipulative Treatment (OMT) 13.22.3.1. Surgery 13.22.3.2. Others 13.23. ASEAN Piriformis Syndrome Market Forecast, By End-User 13.23.1. Hospitals & Clinics 13.23.2. Diagnostic Centers 13.23.3. Other 13.24. Rest of Asia Pacific Piriformis Syndrome Market Forecast, By Cause 13.24.1. Trauma 13.24.2. Spasms 13.24.3. Overuse injury 13.24.4. Other 13.25. Rest of Asia Pacific Piriformis Syndrome Market Forecast, By Treatment 13.25.1. Medication 13.25.1.1. NSAIDS 13.25.1.1.1. Naproxen 13.25.1.1.2. Ibuprofen 13.25.1.1.3. Others 13.25.1.2. Piriformis Muscle Injection 13.25.1.2.1. Botox Injection 13.25.1.2.2. Steroid Injection 13.25.1.2.3. Others 13.25.2. Physical Therapy 13.25.2.1. Acupuncture 13.25.2.2. Prolotherapy 13.25.3. Osteopathic Manipulative Treatment (OMT) 13.25.3.1. Surgery 13.25.3.2. Others 13.26. Rest of Asia Pacific Piriformis Syndrome Market Forecast, By End-User 13.26.1. Hospitals & Clinics 13.26.2. Diagnostic Centers 13.26.3. Other 13.27. Asia Pacific Piriformis Syndrome Market Attractiveness Analysis 13.27.1. By Cause 13.27.2. By Treatment 13.27.3. By End-User 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Piriformis Syndrome Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Piriformis Syndrome Market Overview 14.3. Middle East & Africa Piriformis Syndrome Market Value Share Analysis, By Cause 14.4. Middle East & Africa Piriformis Syndrome Market Forecast, By Cause 14.4.1. Trauma 14.4.2. Spasms 14.4.3. Overuse injury 14.4.4. Other 14.5. Middle East & Africa Piriformis Syndrome Market Value Share Analysis, By Treatment 14.6. Middle East & Africa Piriformis Syndrome Market Forecast, By Treatment 14.6.1. Medication 14.6.1.1. NSAIDS 14.6.1.1.1. Naproxen 14.6.1.1.2. Ibuprofen 14.6.1.1.3. Others 14.6.1.2. Piriformis Muscle Injection 14.6.1.2.1. Botox Injection 14.6.1.2.2. Steroid Injection 14.6.1.2.3. Others 14.6.2. Physical Therapy 14.6.2.1. Acupuncture 14.6.2.2. Prolotherapy 14.6.3. Osteopathic Manipulative Treatment (OMT) 14.6.3.1. Surgery 14.6.3.2. Others 14.7. Middle East & Africa Piriformis Syndrome Market Value Share Analysis, By End-User 14.8. Middle East & Africa Piriformis Syndrome Market Forecast, By End-User 14.8.1. Hospitals & Clinics 14.8.2. Diagnostic Centers 14.8.3. Other 14.9. Middle East & Africa Piriformis Syndrome Market Value Share Analysis, by Country 14.10. Middle East & Africa Piriformis Syndrome Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Piriformis Syndrome Market Analysis, by Country 14.12. GCC Piriformis Syndrome Market Forecast, By Cause 14.12.1. Trauma 14.12.2. Spasms 14.12.3. Overuse injury 14.12.4. Other 14.13. GCC Piriformis Syndrome Market Forecast, By Treatment 14.13.1. Medication 14.13.1.1. NSAIDS 14.13.1.1.1. Naproxen 14.13.1.1.2. Ibuprofen 14.13.1.1.3. Others 14.13.1.2. Piriformis Muscle Injection 14.13.1.2.1. Botox Injection 14.13.1.2.2. Steroid Injection 14.13.1.2.3. Others 14.13.2. Physical Therapy 14.13.2.1. Acupuncture 14.13.2.2. Prolotherapy 14.13.3. Osteopathic Manipulative Treatment (OMT) 14.13.3.1. Surgery 14.13.3.2. Others 14.14. GCC Piriformis Syndrome Market Forecast, By End-User 14.14.1. Hospitals & Clinics 14.14.2. Diagnostic Centers 14.14.3. Other 14.15. South Africa Piriformis Syndrome Market Forecast, By Cause 14.15.1. Trauma 14.15.2. Spasms 14.15.3. Overuse injury 14.15.4. Other 14.16. South Africa Piriformis Syndrome Market Forecast, By Treatment 14.16.1. Medication 14.16.1.1. NSAIDS 14.16.1.1.1. Naproxen 14.16.1.1.2. Ibuprofen 14.16.1.1.3. Others 14.16.1.2. Piriformis Muscle Injection 14.16.1.2.1. Botox Injection 14.16.1.2.2. Steroid Injection 14.16.1.2.3. Others 14.16.2. Physical Therapy 14.16.2.1. Acupuncture 14.16.2.2. Prolotherapy 14.16.3. Osteopathic Manipulative Treatment (OMT) 14.16.3.1. Surgery 14.16.3.2. Others 14.17. South Africa Piriformis Syndrome Market Forecast, By End-User 14.17.1. Hospitals & Clinics 14.17.2. Diagnostic Centers 14.17.3. Other 14.18. Rest of Middle East & Africa Piriformis Syndrome Market Forecast, By Cause 14.18.1. Trauma 14.18.2. Spasms 14.18.3. Overuse injury 14.18.4. Other 14.19. Rest of Middle East & Africa Piriformis Syndrome Market Forecast, By Treatment 14.19.1. Medication 14.19.1.1. NSAIDS 14.19.1.1.1. Naproxen 14.19.1.1.2. Ibuprofen 14.19.1.1.3. Others 14.19.1.2. Piriformis Muscle Injection 14.19.1.2.1. Botox Injection 14.19.1.2.2. Steroid Injection 14.19.1.2.3. Others 14.19.2. Physical Therapy 14.19.2.1. Acupuncture 14.19.2.2. Prolotherapy 14.19.3. Osteopathic Manipulative Treatment (OMT) 14.19.3.1. Surgery 14.19.3.2. Others 14.20. Middle East & Africa Piriformis Syndrome Market Forecast, By End-User 14.20.1. Hospitals & Clinics 14.20.2. Diagnostic Centers 14.20.3. Other 14.21. Middle East & Africa Piriformis Syndrome Market Attractiveness Analysis 14.21.1. By Cause 14.21.2. By Treatment 14.21.3. By End-User 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Piriformis Syndrome Market Analysis 15.1. Key Findings 15.2. South America Piriformis Syndrome Market Overview 15.3. South America Piriformis Syndrome Market Value Share Analysis, By Cause 15.4. South America Piriformis Syndrome Market Forecast, By Cause 15.4.1. Trauma 15.4.2. Spasms 15.4.3. Overuse injury 15.4.4. Other 15.5. South America Piriformis Syndrome Market Value Share Analysis, By Treatment 15.6. South America Piriformis Syndrome Market Forecast, By Treatment 15.6.1. Medication 15.6.1.1. NSAIDS 15.6.1.1.1. Naproxen 15.6.1.1.2. Ibuprofen 15.6.1.1.3. Others 15.6.1.2. Piriformis Muscle Injection 15.6.1.2.1. Botox Injection 15.6.1.2.2. Steroid Injection 15.6.1.2.3. Others 15.6.2. Physical Therapy 15.6.2.1. Acupuncture 15.6.2.2. Prolotherapy 15.6.3. Osteopathic Manipulative Treatment (OMT) 15.6.3.1. Surgery 15.6.3.2. Others 15.7. South America Piriformis Syndrome Market Value Share Analysis, By End-User 15.8. South America Piriformis Syndrome Market Forecast, By End-User 15.8.1. Hospitals & Clinics 15.8.2. Diagnostic Centers 15.8.3. Other 15.9. South America Piriformis Syndrome Market Value Share Analysis, by Country 15.10. South America Piriformis Syndrome Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Piriformis Syndrome Market Analysis, by Country 15.12. Brazil Piriformis Syndrome Market Forecast, By Cause 15.12.1. Trauma 15.12.2. Spasms 15.12.3. Overuse injury 15.12.4. Other 15.13. Brazil Piriformis Syndrome Market Forecast, By Treatment 15.13.1. Medication 15.13.1.1. NSAIDS 15.13.1.1.1. Naproxen 15.13.1.1.2. Ibuprofen 15.13.1.1.3. Others 15.13.1.2. Piriformis Muscle Injection 15.13.1.2.1. Botox Injection 15.13.1.2.2. Steroid Injection 15.13.1.2.3. Others 15.13.2. Physical Therapy 15.13.2.1. Acupuncture 15.13.2.2. Prolotherapy 15.13.3. Osteopathic Manipulative Treatment (OMT) 15.13.3.1. Surgery 15.13.3.2. Others 15.14. Brazil Piriformis Syndrome Market Forecast, By End-User 15.14.1. Hospitals & Clinics 15.14.2. Diagnostic Centers 15.14.3. Other 15.15. Mexico Piriformis Syndrome Market Forecast, By Cause 15.15.1. Trauma 15.15.2. Spasms 15.15.3. Overuse injury 15.15.4. Other 15.16. Mexico Piriformis Syndrome Market Forecast, By Treatment 15.16.1. Medication 15.16.1.1. NSAIDS 15.16.1.1.1. Naproxen 15.16.1.1.2. Ibuprofen 15.16.1.1.3. Others 15.16.1.2. Piriformis Muscle Injection 15.16.1.2.1. Botox Injection 15.16.1.2.2. Steroid Injection 15.16.1.2.3. Others 15.16.2. Physical Therapy 15.16.2.1. Acupuncture 15.16.2.2. Prolotherapy 15.16.3. Osteopathic Manipulative Treatment (OMT) 15.16.3.1. Surgery 15.16.3.2. Others 15.17. Mexico Piriformis Syndrome Market Forecast, By End-User 15.17.1. Hospitals & Clinics 15.17.2. Diagnostic Centers 15.17.3. Other 15.18. Rest of South America Piriformis Syndrome Market Forecast, By Cause 15.18.1. Trauma 15.18.2. Spasms 15.18.3. Overuse injury 15.18.4. Other 15.19. Rest of South America Piriformis Syndrome Market Forecast, By Treatment 15.19.1. Medication 15.19.1.1. NSAIDS 15.19.1.1.1. Naproxen 15.19.1.1.2. Ibuprofen 15.19.1.1.3. Others 15.19.1.2. Piriformis Muscle Injection 15.19.1.2.1. Botox Injection 15.19.1.2.2. Steroid Injection 15.19.1.2.3. Others 15.19.2. Physical Therapy 15.19.2.1. Acupuncture 15.19.2.2. Prolotherapy 15.19.3. Osteopathic Manipulative Treatment (OMT) 15.19.3.1. Surgery 15.19.3.2. Others 15.20. Rest of South America Piriformis Syndrome Market Forecast, By End-User 15.20.1. Hospitals & Clinics 15.20.2. Diagnostic Centers 15.20.3. Other 15.21. South America Piriformis Syndrome Market Attractiveness Analysis 15.21.1. By Cause 15.21.2. By Treatment 15.21.3. By End-User 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Sanofi S.A.. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Bayer AG 16.3.3. Novartis AG 16.3.4. AstraZeneca 16.3.5. Endo Pharmaceuticals 16.3.6. Teva Pharmaceuticals 16.3.7. Omron Healthcare 16.3.8. DePuy Synthes Companies 16.3.9. Miracle Stretch, LLC 16.3.10. Flex Pharma, Inc. 16.3.11. Nidd valley medical 16.3.12. SEIRIN Corporation 17. Primary Key Insights

About This Report

Report ID 70140
Category Healthcare
Published Date Auguet2020
Updated Date
Contact Us